Brief: Virios Therapeutics Achieves Over 50% Enrollment Milestone In Its Phase 2B Clinical Trial For Fibromyalgia

Dogwood Therapeutics

01/12/2021 12:24

Dec 1 (Reuters) - Virios Therapeutics Inc  VIRI.O :
    * VIRIOS THERAPEUTICS ACHIEVES OVER 50% ENROLLMENT MILESTONE
IN
ITS PHASE 2B CLINICAL TRIAL FOR FIBROMYALGIA
    * VIRIOS THERAPEUTICS INC - PHASE 2B CLINICAL TRIAL BUILDS
ON
POSITIVE PHASE 2A DATA
    * VIRIOS THERAPEUTICS INC - 143-PATIENT PHASE 2A TRIAL
DEMONSTRATED THAT IMC-1 MET ITS PRIMARY ENDPOINT OF PAIN
REDUCTION
    * VIRIOS THERAPEUTICS INC - REACHING ENROLLMENT MILESTONE ON
TIMELY BASIS INDICATES THAT WE ARE ON TRACK TO REPORT TOP LINE
RESULTS IN Q3 OF 2022

Source text for Eikon:  ID:nBwpHPX2a 
Further company coverage:  VIRI.O 

 ((Reuters.Briefs@thomsonreuters.com;))